T‐cell responses and therapies against SARS‐CoV‐2 infection

Toor, SM ORCID: https://orcid.org/0000-0002-4683-3329, Saleh, R ORCID: https://orcid.org/0000-0002-8292-1895, Sasidharan Nair, V ORCID: https://orcid.org/0000-0001-5047-2338, Taha, RZ ORCID: https://orcid.org/0000-0001-6119-8389 and Elkord, E ORCID: https://orcid.org/0000-0002-3868-0318 2021, 'T‐cell responses and therapies against SARS‐CoV‐2 infection' , Immunology, 162 (1) , pp. 30-43.

PDF - Published Version
Available under License Creative Commons Attribution 4.0.

Download (713kB) | Preview


Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2, a novel coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double‐edge sword with both pro‐ and anti‐roles in the progression of COVID‐19. Thus, better understanding of their roles in immune responses to SARS‐CoV‐2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T‐cell responses can be suboptimal, impaired or excessive in severe COVID‐19 patients. This review focuses on the multifaceted roles of T cells in COVID‐19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID‐19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID‐19 patients. These include adoptive T‐cell therapies, vaccines activating T‐cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti‐inflammatory drugs to improve antiviral T‐cell responses against SARS‐CoV‐2.

Item Type: Article
Additional Information: ** Article version: VoR ** From Crossref journal articles via Jisc Publications Router ** Licence for VoR version of this article starting on 27-10-2020: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: pissn 0019-2805; eissn 1365-2567 **History: issued 27-10-2020; published_online 27-10-2020
Schools: Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title: Immunology
Publisher: Wiley
ISSN: 0019-2805
Related URLs:
SWORD Depositor: Publications Router
Depositing User: Publications Router
Date Deposited: 12 Nov 2020 09:56
Last Modified: 16 Feb 2022 05:59
URI: https://usir.salford.ac.uk/id/eprint/58784

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)


Downloads per month over past year